Unknown

Dataset Information

0

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

ABSTRACT: The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.

SUBMITTER: Holstein SA 

PROVIDER: S-EPMC6445685 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein Sarah A SA   Ye J Christine JC   Howard Alan A   Bhutani Manisha M   Gormley Nicole N   Hahn Theresa T   Hillengass Jens J   Krishnan Amrita A   Landgren C Ola CO   Munshi Nikhil C NC   Oliva Stefania S   Owen Roger G RG   Pasquini Marcelo C MC   Puig Noemi N   Weinhold Niels N   Weisel Katja K   McCarthy Philip L PL  

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20181105 3

The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant A  ...[more]

Similar Datasets

Unknown BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
| S-EPMC5902638 | biostudies-literature
Unknown The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
| S-EPMC8478786 | biostudies-literature
Unknown Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
| S-EPMC6942175 | biostudies-literature
Unknown Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
| S-EPMC7529908 | biostudies-literature
Unknown A Summary of the Third Annual HIV Microbiome Workshop.
| S-EPMC6422011 | biostudies-literature
Unknown Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
| S-EPMC6553842 | biostudies-literature
Unknown A Summary of the Fifth Annual Virology Education HIV Microbiome Workshop.
| S-EPMC7869876 | biostudies-literature
Unknown Minimal residual disease in multiple myeloma: current status.
| S-EPMC8515655 | biostudies-literature
Unknown Minimal residual disease in multiple myeloma: why, when, where.
| S-EPMC8791109 | biostudies-literature
Unknown Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
| S-EPMC10690096 | biostudies-literature